NorthCrest Asset Manangement LLC Purchases 1,843 Shares of United Therapeutics Corporation $UTHR

NorthCrest Asset Manangement LLC grew its position in United Therapeutics Corporation (NASDAQ:UTHR) by 32.4% in the 4th quarter, according to its most recent filing with the SEC. The firm owned 7,537 shares of the biotechnology company’s stock after buying an additional 1,843 shares during the period. NorthCrest Asset Manangement LLC’s holdings in United Therapeutics were worth $3,691,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently made changes to their positions in UTHR. AQR Capital Management LLC boosted its holdings in United Therapeutics by 40.1% in the second quarter. AQR Capital Management LLC now owns 1,273,161 shares of the biotechnology company’s stock valued at $362,876,000 after acquiring an additional 364,713 shares during the last quarter. Invesco Ltd. raised its holdings in United Therapeutics by 90.2% during the 2nd quarter. Invesco Ltd. now owns 884,703 shares of the biotechnology company’s stock worth $254,219,000 after purchasing an additional 419,588 shares during the last quarter. Darwin Global Management Ltd. bought a new stake in United Therapeutics during the 3rd quarter worth about $317,617,000. Norges Bank acquired a new position in United Therapeutics during the 2nd quarter valued at about $136,453,000. Finally, Amundi boosted its stake in shares of United Therapeutics by 3.6% in the 2nd quarter. Amundi now owns 362,826 shares of the biotechnology company’s stock valued at $107,113,000 after purchasing an additional 12,633 shares during the last quarter. Institutional investors own 94.08% of the company’s stock.

Wall Street Analysts Forecast Growth

Several brokerages have recently commented on UTHR. Wells Fargo & Company lifted their price target on shares of United Therapeutics from $423.00 to $466.00 and gave the stock an “equal weight” rating in a research report on Thursday, February 26th. TD Cowen raised their price objective on shares of United Therapeutics from $525.00 to $575.00 and gave the company a “buy” rating in a research note on Wednesday, February 25th. Cantor Fitzgerald upped their target price on shares of United Therapeutics from $525.00 to $625.00 and gave the company an “overweight” rating in a research report on Thursday, March 12th. UBS Group increased their price target on United Therapeutics from $655.00 to $705.00 and gave the company a “buy” rating in a research note on Thursday, March 5th. Finally, Weiss Ratings restated a “buy (b)” rating on shares of United Therapeutics in a research report on Monday, December 29th. Nine research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $548.09.

Insider Buying and Selling

In other news, CEO Martine A. Rothblatt sold 9,500 shares of the firm’s stock in a transaction that occurred on Wednesday, March 18th. The shares were sold at an average price of $529.59, for a total transaction of $5,031,105.00. Following the completion of the transaction, the chief executive officer directly owned 40,513 shares of the company’s stock, valued at $21,455,279.67. This trade represents a 19.00% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Paul A. Mahon sold 8,300 shares of United Therapeutics stock in a transaction that occurred on Thursday, March 19th. The shares were sold at an average price of $529.95, for a total transaction of $4,398,585.00. Following the completion of the sale, the executive vice president owned 45,172 shares in the company, valued at $23,938,901.40. This trade represents a 15.52% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders sold 318,870 shares of company stock worth $156,760,844. 10.30% of the stock is owned by insiders.

United Therapeutics Stock Performance

UTHR opened at $524.28 on Monday. The firm has a market cap of $22.98 billion, a PE ratio of 18.79, a price-to-earnings-growth ratio of 1.89 and a beta of 0.84. United Therapeutics Corporation has a twelve month low of $266.98 and a twelve month high of $548.12. The firm’s fifty day moving average is $490.39 and its two-hundred day moving average is $468.92.

United Therapeutics (NASDAQ:UTHR) last announced its quarterly earnings results on Wednesday, February 25th. The biotechnology company reported $7.70 earnings per share (EPS) for the quarter, topping the consensus estimate of $6.78 by $0.92. United Therapeutics had a return on equity of 19.30% and a net margin of 41.94%.The company had revenue of $790.20 million during the quarter, compared to the consensus estimate of $814.80 million. During the same period in the prior year, the company earned $6.19 earnings per share. The company’s revenue for the quarter was up 7.4% compared to the same quarter last year. Equities analysts forecast that United Therapeutics Corporation will post 24.48 EPS for the current fiscal year.

About United Therapeutics

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.